NeuroAiD presentations at European Stroke Organisation Conference
NeuroAiD presentations at European Stroke Organisation Conference NeuroAiD, Moleac’s main product, will be presented at the 3rd European Stroke Organisation Conference on 16th May during the following poster presentations: Synergistic Effect of Combining MLC601 and...
Launch of NeuroAiD in Nigeria
Launch of NeuroAiD in Nigeria Helping patients reconnect with their lives remain our focus. This February, NeuroAiD will be launched in Nigeria in association with our local distributor, Bolar Pharmaceuticals. Nigeria is one of the most populous nations in Africa, and...
Moleac awarded prize from Creative France – recognising the success of French entrepreneurs in Singapore
Moleac awarded prize from Creative France – recognising the success of French entrepreneurs in Singapore “Entrepreneur” is a French invention for risk takers committed to innovate, and Moleac is a complete illustration of successful entrepreneurial biopharmaceutical...
Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAiD™) in the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study
Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAiD™) in the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study Cerebrovasc Dis 2017; 43:36-42 Published by S. Karger AG, Basel This analysis from the CHIMES-E study shows that...
